Prestige Biopharma Limited sell "HD204 (Bevacizumab biosimilar)"
Basic Information
1.1K
80
20
3.9(18)
Category
Subcategory & Sub-subcategory
Trade Type
Sell
Product Name
HD204 (Bevacizumab biosimilar)
Manufacturer(s)
Specifications
- Application: Bevacizumab (Avastin®) biosimilar candidate used to treat cancers including metastatic colorectal cancer, non-small-cell lung cancer, renal cell cancer, ovarian cancer and metastatic breast cancer
- Regulatory Status: Global Phase 3 clinical trial completed
- Certification Standard: Developed as a biosimilar candidate intended to demonstrate analytical and clinical equivalence to the reference product bevacizumab (Avastin®)
Other Information
Additional Description:
HD204 is a bevacizumab (Avastin®) biosimilar candidate. Bevacizumab treats numerous cancers, often as first-line therapy, including metastatic colorectal cancer, non-small-cell lung cancer, renal cell cancer, ovarian cancer and metastatic breast cancer. A global Phase 3 clinical trial for HD204 has been completed.
Ratings
(0)
(0)
(0)
(0)
(0)
Comments
Filters:
Sort by:
No comments available.
Matched Products & Services
B2B matches based on trade type, category, specifications & price range
Similar Products & Services
Products & Services related to what you're viewing
People Also Viewed
Other products & services viewed by people who looked at this product
Leave your rating & comment